Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21042103 | 0.84 | GPR119 (0.45) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL846218 | 0.83 | HDAC1 (0.53) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL19689700 | 0.83 | GPR119 (0.47) | GPR119NOTUMDHODHKDM4EALDH1A1 | |
| SCHEMBL380505 | 0.83 | DHODH (0.49) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL30527088 | 0.83 | DHODH (0.49) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL21724876 | 0.82 | GPR119 (0.46) | GPR119NOTUMCHRM4DRD2HTR7 | |
| SCHEMBL30681278 | 0.81 | GPR119 (0.45) | GPR119NOTUMCHRM4DRD2HTR7 | |
| SCHEMBL5077828 | 0.81 | NR1H2 (0.62) | GPR119KDM4EMAPTRAB9AHDAC1 | |
| SCHEMBL1365223 | 0.81 | ESR2 (0.63) | GPR119KDM4EMAPTHDAC1HDAC6 | |
| SCHEMBL19689701 | 0.80 | ALDH1A1 (0.51) | GPR119DHODHKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | ELI LILLY AND COMPANY (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3468965-B1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | LILLY CO ELI (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY | 2019-05-30 | — | — | US | disclosed |
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY | 2019-05-30 | — | — | US | disclosed |
| EP-3468965-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | Eli Lilly and Company (US) | 2019-04-17 | — | — | EP | disclosed |
| US-9872853-B2 | 2,3-dihydro-1H-indole compounds | ELI LILLY AND COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872853-B2 | 2,3-dihydro-1H-indole compounds | ELI LILLY AND COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY | 2017-12-14 | — | — | US | disclosed |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | ELI LILLY AND COMPANY | 2017-12-14 | — | — | US | disclosed |
| WO-2017213919-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017213919-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER | ELI LILLY AND COMPANY (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161477-A1 | 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER | MCL1, IDO1, GLI1 | GPR119 120/4885PDK1 140/4885PDK2 426/4885 |
| US-10759786-B2 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer | MCL1, FOXM1, IDO1 | GPR119 266/4885PDK1 90/4885PDK2 236/4885 |
| US-20170354641-A1 | 2,3-DIHYDRO-1H-INDOLE COMPOUNDS | MCL1, IDO1, IDO2 | GPR119 344/4885PDK1 141/4885PDK2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.